用sorafenib治疗晚期肝细胞癌:为期10年的单一中心经验
José Presa Ramos1, Sofia Tavares2, Ana Barreira1
1Liver Unit, Internal Medicine Department, Centro Hospitalar de Trás-os-Montes e Alto Douro, Hospital de Vila Real, Vila Real, Portugal.
GE Portuguese journal of gastroenterology
|June 30, 2023
概括
索拉菲尼布是治疗不可切除的肝细胞癌 (HCC) 的可行的治疗方法. 较低的α-fetoprotein (AFP) 水平预测了更好的生存率,而损伤大小和宏血管入侵影响结果.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 医学瘤学 医学瘤学
背景情况:
- 索拉费尼布是治疗不可切除的肝细胞癌 (HCC) 的第一个全身疗法.
- 之前已经确定了索拉芬尼治疗的预后因素.
研究的目的:
- 评估使用索拉芬尼布治疗的HCC患者的存活率和进展时间 (TTP).
- 为了确定索拉芬尼在HCC患者中受益的预测因素.
主要方法:
- 对从2008年至2018年接受索拉芬尼治疗的HCC患者的回顾性分析.
- 收集的数据包括患者人口统计,临床因素,生存率,TTP和不良事件.
主要成果:
- 平均存活时间为10个月,中位数TTP为5个月.
- 更大的病变大小 (LS) 和更高的α-fetoprotein (AFP) 与死亡率有关.
- 宏观血管侵袭 (MVI) 是较短TTP的独立预测因素.
结论:
- 索拉费尼布仍然是高级HCC的可行选择.
- 较低的LS和AFP与更好的结果有关;较低的AFP是生存的关键预测因素.
- 在Child-Pugh A和B患者之间没有观察到生存或TTP的显著差异.
相关概念视频
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K